Bluschke, Annet
Eggert, Elena
Friedrich, Julia
Jamous, Roula
Prochnow, Astrid
Pscherer, Charlotte
Schreiter, Marie Luise
Teufert, Benjamin
Roessner, Veit
Beste, Christian
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2016_A94)
Friede Springer Stiftung (033/2017)
Technische Universität Dresden
Article History
Received: 31 May 2021
Accepted: 20 October 2022
First Online: 4 November 2022
Declarations
:
: The study was conducted according to the Declaration of Helsinki and approved by the ethics committee of the Medical Faculty of the TU Dresden.
: Written informed consent was obtained from all study participants and their legal guardians.
: Written informed consent was obtained from all study participants and their legal guardians. The ethics committee approved publication in anonymized form.
: A.B., E.E., J.F., R.J., A.P., C.P., M.L.S. and B.T. declare no conflicts of interest. V.R. has received payment for consulting and writing activities from Lilly, Novartis and Shire Pharmaceuticals; lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals and Medice Pharma; and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire and Otsuka companies. C.B. has received payment for consulting from GlaxoSmithKline, Novartis, Genzyme and Teva.